Good morning. It's August 22.

Newsflash: exercise makes you biologically younger. Not metaphorically - measurably, at the molecular level. A new study in GeroScience shows that the fitness gains from cardio show up directly in the epigenetic clocks researchers use to track cellular aging.

Also this week: the FDA's decision on making lecanemab available without any intravenous infusion - ever - lands Monday. And the team behind the Forever Young documentary just launched a course based on interviews with the A-team of longevity scientists.

The rundown for this week:

Let's get to it. 👇

Nearly half of dementia cases may be linked to risks you can actually change - a long-term brain study found that common factors including smoking, high blood pressure, heart disease, and high blood lipids were strongly linked to damage associated with vascular dementia. The findings reinforce that lifestyle choices made over decades show up clearly in brain tissue decades later. ScienceDaily

Even under the most favorable biological conditions, DNA mutation accumulation may limit human lifespan to between 146 and 194 years - a new study probes the upper boundaries of the human lifespan, finding that even if all environmental and lifestyle factors were perfect, somatic mutations (random DNA copying errors that accumulate in every cell division throughout life) create a biological ceiling. Healthline

Niagen Bioscience has partnered with Evotec to advance NB4168 - an oral NAD+ small molecule for a rare pediatric neurodegenerative disease - NAD+ is the coenzyme central to cellular energy production and DNA repair that declines with age. This deal signals that NAD+ science is maturing beyond the supplement aisle into genuine pharmaceutical development. Longevity.Technology

Scientists restored about two hours of sleep in Alzheimer's mice by targeting the brain's own immune cells - the culprit wasn't plaques or tangles but microglia (the brain's resident immune cells) that were driving sleep disruption. Clearing amyloid plaques alone didn't fix it - but targeting microglia did. ScienceDaily

NIH awarded $7.5 million to USC to launch a research center specifically studying sex differences in aging - decades of aging research has used predominantly male subjects, leaving significant gaps in how longevity interventions work in women. This center is designed to close that gap and reshape biomarkers, clinical trials, and personalized protocols accordingly. Longevity.Technology

In 2002, the Women's Health Initiative published findings that scared millions of women off hormone therapy overnight. The study linked combined estrogen-progestin HRT to increased risks of breast cancer and heart disease - and HRT use dropped by half in the years that followed.

What got lost in the fallout: the details. The WHI studied older women using a specific combined hormone formulation, not estrogen alone. And a growing body of research since then has been quietly building a different case.

A new study of more than 21,000 participants published in August is the latest addition to that case. Women who used estrogen-only hormone therapy later in life were less likely to develop dementia - and their brains showed fewer of the structural changes associated with Alzheimer's disease when examined post-mortem.

A few important distinctions:

This doesn't change clinical recommendations, and it doesn't mean every postmenopausal woman should start estrogen therapy. What it does is add to a body of evidence that the 2002 WHI findings were misapplied to a much broader population than the study actually covered.

If you're in or approaching menopause, this is worth a conversation with your doctor - not a decision to make based on a newsletter.

👉 ScienceDaily

Producers of the longevity documentary Forever Young spent many hours filming & interviewing the world's top longevity scientists - the founders of the field.

Today they launch The Long Game: a 21-chapter deep dive into the science of longevity, featuring contributions from scientists you don't normally get in the same room:

This is not a summary course. This is exclusive access to the people doing the scientific breakthrough work. Twenty-one chapters that build the foundation to evaluate longevity science yourself - rather than taking anyone else's word for it.

Early bird pricing limited to the first 50 students.

👉 Get early access to The Long Game - use code STAYINALIVE for 25% off (expires in a week)

The exercise-longevity connection is not news. Every major longevity researcher will tell you aerobic fitness is the most evidence-backed lever for extending healthspan. What's been harder to prove is exactly how it works at the molecular level - and whether the benefits show up in biological aging measurements, or just in the physical health markers we can see.

A new study published in GeroScience answers that. Measuring changes in epigenetic clocks before and after a structured fitness program, researchers found that meaningful improvements in cardiorespiratory fitness produced measurable deceleration in the rate of biological aging.

Epigenetic clocks - sometimes called DNA methylation clocks - work by tracking how the chemical tags on your DNA shift over time. These shifts happen in predictable patterns as cells age and accumulate damage, making them one of the most reliable estimates of biological age currently available. The same tools that aging researchers use to measure whether an intervention is actually slowing aging at the cellular level.

The science breakdown:

This is a pilot study - the sample size is small and the findings need replication at scale. But the directional signal is exactly what the field has been looking for: the biological aging benefits of sustained cardiovascular exercise aren't just theoretical. They appear to be measurable in the molecular clocks that longevity researchers use to track aging itself.

The practical upshot is the same message it has always been. What's new is the molecular fingerprint that captures it. Cardiovascular fitness doesn't just reduce your risk of dying from heart disease. It may actually slow the rate at which your cells age.

👉 GeroScience (full study)

On August 24 - this Monday - the FDA is expected to rule on whether Alzheimer's patients can start lecanemab treatment entirely at home, by self-injection, with no IV infusion center required. Ever.

This sounds procedural. It isn't.

Lecanemab - sold as Leqembi - is the most widely approved Alzheimer's drug in the world. Approved in 53 countries. Three years of real-world data from the LEADER study showed 83% of patients staying stable or improving over 17 months. It works. The problem is getting it to patients.

Right now, starting lecanemab requires intravenous infusions at specialized infusion centers - administered every two weeks for the first 18 months of treatment. That's a significant infrastructure barrier. Urban patients with nearby facilities can access it. Millions of others - rural patients, people without the ability to travel regularly, elderly patients for whom frequent clinical visits are genuinely burdensome - effectively cannot.

The pending FDA decision on LEQEMBI IQLIK removes that barrier entirely. The application seeks approval for a once-weekly subcutaneous autoinjector - a self-injection pen - as the starting dose. Patients could begin and complete the full treatment course at home. The FDA already approved this formulation for maintenance dosing in August 2025. Monday's decision covers the initiation phase. If it goes through, the IV infusion requirement disappears from every step of lecanemab treatment.

The FDA has not raised any concerns about approvability. The agency extended the review by 3 months in May only because Eisai submitted additional data as part of normal review - a procedural extension, not a signal of any problem with the drug.

If approved Monday, the addressable patient population for the most effective Alzheimer's drug currently available expands dramatically. That matters for patients. It also matters for every longevity investor and clinical operator paying attention to neurodegenerative disease. Watch August 24.

👉 NeurologyLive | Biogen

Pique’s new X·E Fountain energy drink delivers clean, caffeine-free energy without the jitters, crash, or dehydration. Vitamin B Complex, magnesium, and electrolytes help support steady focus, while crisp cucumber-celery-lime makes every sip ridiculously refreshing.

Get 15% off for life.

This week's From the Clinic showed that getting aerobically fitter doesn't just improve your health markers - it measurably slows your biological clock. Lieberman explains why your body was built for exactly this.

Lieberman is a professor of evolutionary biology at Harvard and one of the world's leading researchers on human physical activity. The book answers a question that turns out to be surprisingly revealing: if humans evolved as physically active hunters and gatherers, why does exercise feel hard? And why, if it's so clearly good for us, do so many people avoid it?

The answer traces back to evolutionary biology. We evolved to be physically active - but also to rest whenever possible, because conserving energy was essential for survival. The result is a body that needs physical stress to function well, but a brain wired to avoid unnecessary exertion. Understanding that tension doesn't just explain why the gym feels hard. It explains why chronic sedentary behavior is so damaging, what types of movement our biology actually needs, and why the relationship between exercise and aging goes deeper than calorie burn and cardiovascular fitness.

The exercise chapter in From the Clinic is the news. This is the mechanism behind it.

👉 Get Exercised

Superpower charges just $199 for 100+ biomarkers, a personalized action plan, and 24/7 access to a care team.

(This section contains an affiliate link - if you buy through it, we may earn a commission at no extra cost to you.)

How to fix a broken heart 👇

Ad slots are filling up fast. To promote your longevity / biohacking product to our niche audience, see the media kit and get in touch with Sebastian at [email protected]